Literature DB >> 1920341

Does treated essential hypertension result in renal impairment? A cohort study.

C R Tomson1, K Petersen, A M Heagerty.   

Abstract

To determine how frequently essential hypertension results in significant renal impairment we undertook a follow-up study of 176 patients with well documented essential hypertension first seen in 1975-1977. Six patients were Asian, two Negro, and the remainder Europid. Follow-up was achieved in 92% of the cohort at five years and in 87% at 12-14 years. At five years 13 (7%) patients had moved away or were lost, and 15 (9%) patients had died (11 cardiovascular deaths). Treated blood pressure was greater than 160/95 mmHg in 60/148 patients and greater than 200/100 mmHg in 16 patients. Despite this, no significant change in serum creatinine was detected in the group as a whole. Increments in serum creatinine of at least 35 mumol/l occurred in six patients. Over the ensuing 6-9 years serum creatinine had returned to normal in three of these patients and stabilized in two; the sixth patient died from myocardial infarction. No patient reached end-stage renal failure. We conclude that progressive deterioration in renal function in essential hypertension is rarely a significant problem in Caucasian patients. A decline in renal function should prompt a search for underlying primary renal disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1920341

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  2 in total

1.  Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population.

Authors:  Naoki Shiraishi; Kenichiro Kitamura; Yukimasa Kohda; Kunitoshi Iseki; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2013-07-06       Impact factor: 2.801

Review 2.  The kidney as a target of hypertension.

Authors:  S Ljungman
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.